E Diletti
About
In The Last Decade
E Diletti
18 papers receiving 742 citations
Peers
Comparison fields: 5 of 111
- Statistics and Probability 302
- Pediatrics, Perinatology and Child Health 175
- Management Science and Operations Research 143
- Pharmacology 129
- Pharmacology 126
Countries citing papers authored by E Diletti
This map shows the geographic impact of E Diletti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E Diletti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E Diletti more than expected).
Fields of papers citing papers by E Diletti
This network shows the impact of papers produced by E Diletti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E Diletti. The network helps show where E Diletti may publish in the future.
Co-authorship network of co-authors of E Diletti
This figure shows the co-authorship network connecting the top 25 collaborators of E Diletti. A scholar is included among the top collaborators of E Diletti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E Diletti. E Diletti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 30 | |
| 2 | 64 | |
| 3 | 1 | |
| 4 | 6 | |
| 5 | Interobserver agreement: Cohen's kappa coefficient does not necessarily reflect the percentage of patients with congruent classifications. | 24 |
| 6 | 5 | |
| 7 | Reference tables for the intrasubject coefficient of variation in bioequivalence studies. | 31 |
| 8 | Relative bioavailability of different valproic acid formulations. | 3 |
| 9 | Presentation of the intrasubject coefficient of variation for sample size planning in bioequivalence studies. | 14 |
| 10 | Effect of changing the bioequivalence range from (0.80, 1.20) to (0.80, 1.25) on the power and sample size. | 10 |
| 11 | Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43. | 26 |
| 12 | 52 | |
| 13 | Presentation of results from bioequivalence studies. | 60 |
| 14 | Sample size determination for bioequivalence assessment by means of confidence intervals. | 188 |
| 15 | A distribution-free procedure for the statistical analysis of bioequivalence studies. | 194 |
| 16 | Validation of the in-vitro dissolution method used for a new sustained-release theophylline pellet formulation. | 1 |
| 17 | 24 | |
| 18 | 108 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.